Symphogen

Develops antibodies for cancer treatments

Total raised

€287M

€286,954,544

Funding rounds

Investors

distinct backers

Active since

2004-10

latest 2015-09

Funding by year

EUR raised per year

High confidence

Raise-next likelihood18

base rate 45% for Debt

Exit likelihood28

base rate 12% (2+ rounds)

Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

6 rounds

Date	Stage	Amount	Investors
2015-10-01	Debt	€68M	Novo A,S	View deal →
2013-05-01	Growth/Late	€41M	Novo A,S	View deal →
2011-02-01	Series D+	€100M	Essex Woodlands Health Ventures,Novo A,S	View deal →
2009-02-01	Growth/Late	€33M	Essex Woodlands Health Ventures	View deal →
2006-01-01	Series D+	€23M	Essex Woodlands Health Ventures,Gilde Healthcare,Novo A,S,Takeda Ventures	View deal →
2004-11-01	Series C	€23M	Essex Woodlands Health Ventures,Novo A,S	View deal →

same sector or country